Add time:08/28/2019         Source:sciencedirect.com

ObjectiveThe treatment of recurrent respiratory papillomatosis (RRP) continues to be difficult. Adjuvant pharmacological treatment is increasingly being used, and intralesional Cidofovir (cas 113852-37-2) injection remains the leading option. Almost all papers regarding the treatment come from the United States and Europe. The present study demonstrated it for the first time from Asia.

We also recommend Trading Suppliers and Manufacturers of Cidofovir (cas 113852-37-2). Pls Click Website Link as below: cas 113852-37-2 suppliers